Moderna will work from January on an adaptation of its vaccine for the Ómicron variant

Moderna’s vice president, Dan Staner, explained this Tuesday in an interview with French broadcaster RTL that “clinical studies will be launched at the beginning of next year”, once the end of the year holidays are over. .

Staner pointed out that have made the decision to work on “A specific vaccine” , although he recognized that “it will take several months” until it can be administered, taking into account that tests will have to be carried out to verify its efficiency and launch the manufacturing process.

Faced with the eruption of the wave caused by omicron, the “number two” of the pharma The American ceutical company recalled that yesterday they presented the results of the test of their current vaccine against omicron.

He specified that the booster dose of 50 micrograms -half the amount used in each of the first two injections-, increases 37 times the neutralizing antibodies to omicron. In case 100 were administered, the antibodies rise 83 times.

Staner noted that based on those figures, health authorities will assess whether it is worth injecting booster doses of 100 micrograms, at least at people who are most at risk from the coronavirus.

At the end of November, the giant Pfizer said it was going to start work on a new version of its vaccine against omicron, given the possibility that current vaccines show less protection against the new variant.

It may interest you:

· Moderna ensures that her booster dose increases protection against Ómicron

· Court of Appeals reinstates Biden’s COVID vaccine mandate – 19 For businesses

· Report cases of Omicron in 44 states as COVID cases increase – 19 throughout the US